Iantrek appoints Adam Szaronos as CEO
Adam Szaronos has been appointed as CEO of Iantrek, succeeding Sean Ianchulev, MD, MPH, according to a press release.
Szaronos has nearly 20 years of experience in the pharmaceutical, medical device and medical technology sectors, with a focus on targeting unmet needs. He has worked on new technology launches in cataract, refractive and vitreoretinal surgery as well as diagnostics and digital health, the release said. He most recently served as CEO and president of Trukera Medical.
Ianchulev will remain as chairman of the board and chief medical officer at Iantrek.
“As millions of patients fight to prolong the degenerative loss of vision due to glaucoma, the need for interventional treatments to open additional pathways and options for providers has never been greater,” Szaronos said in the release. “Bio-interventional stents and implants, developed from the body’s natural tissue, can uniquely address these needs. Building upon this company’s strong foundation to ensure we now deliver a world-class commercial organization for our physician customers and their patients is my top priority.”
AlloFlo and C-Rex, Iantrek’s first surgical glaucoma products, are currently in a controlled release stage in the United States with plans for a full commercial launch later this year, according to the release.
Read more about